Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...
In patients with severe hemophilia A, standard treatment is regular prophylactic and episodic intravenous infusions of factor VIII. However, these treatments are burdensome, especially for children, ...
Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...
The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector ...
Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...
AFSTYLA ®, Antihemophilic Factor (Recombinant), Single Chain, is contraindicated in patients who have had life-threatening hypersensitivity reactions to AFSTYLA or its excipients, or to hamster ...
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...
Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study No significant financial relationships to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results